Biostar Pharmaceuticals, Inc. (BSPM) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBiostar Pharmaceuticals, Inc. (BSPM) trades at $0.0001. Biostar Pharmaceuticals, Inc. focuses on developing, manufacturing, and marketing pharmaceutical products in China. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for BSPM: BSPM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BSPM against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BSPM: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Biostar Pharmaceuticals, Inc. (BSPM) Healthcare & Pipeline Overview
Biostar Pharmaceuticals, Inc., based in China, develops and markets OTC and prescription pharmaceutical products, including its key product Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B. The company distributes its products across 28 provinces in China, leveraging both distributors and a direct sales network.
What Is the Investment Thesis for BSPM?
Biostar Pharmaceuticals operates in the Chinese pharmaceutical market, focusing on both OTC and prescription drugs. The company's key product, Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B, addresses a significant health issue in China. However, with a negative profit margin of -239.0% and a market capitalization of $0.00B, the company faces significant financial challenges. Potential growth catalysts include expanding its product line and increasing its market penetration within China. Investors should carefully consider the risks associated with investing in OTC-listed companies, including liquidity and disclosure concerns.
Based on FMP financials and quantitative analysis
BSPM Key Highlights
Gross Margin of 38.4% indicates potential for profitability if costs are managed effectively.
- Operates in 28 provinces in China, demonstrating a significant distribution network.
- Offers both OTC and prescription drugs, diversifying its revenue streams.
- Key product, Xin Ao Xing Oleanolic Acid capsule, targets chronic hepatitis B, a significant health issue in China.
- Profit Margin of -239.0% signals financial challenges requiring strategic intervention.
Who Are BSPM's Competitors?
BSPM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals, Inc. | $16.28 | -1.75% | $55.9M | 345-pillar |
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BGM BGM Group Ltd. | $0.28 | +0.92% | $105M | 455-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BSPM's Key Strengths?
Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
What Are BSPM's Weaknesses?
Negative profit margin.
- Limited financial resources.
- Dependence on a single key product (Xin Ao Xing).
- OTC listing indicates higher risk.
What Could Drive BSPM Stock Higher?
Potential regulatory approvals for new pharmaceutical products.
- Expansion of the company's distribution network in China.
- Increased adoption of the China Hepatitis Internet hospital platform.
What Are the Key Risks for BSPM?
Financial-distress signal — its Altman Z-Score of 0.02 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-14.0%) — the business is not currently generating profit on shareholder capital.
- Competition from larger pharmaceutical companies.
- Regulatory changes in China.
- Fluctuations in raw material prices.
- Economic slowdown in China.
- Negative profit margin and limited financial resources.
What Are the Growth Opportunities for BSPM?
- Expanding its OTC product line: Biostar can capitalize on the growing demand for OTC medications in China by introducing new products targeting common ailments. The Chinese OTC market is projected to reach $50 billion by 2028, offering significant revenue potential. Timeline: Launching 2-3 new OTC products annually over the next 3-5 years could significantly boost revenue.
- Increasing market penetration in existing provinces: Biostar currently operates in 28 provinces in China. Deepening its market penetration within these regions through targeted marketing and sales initiatives can drive revenue growth. The pharmaceutical market in these provinces is estimated at $200 billion, offering ample opportunity for expansion. Timeline: Achieving a 1% increase in market share in each province over the next 2 years.
- Leveraging its online platform: Biostar's China Hepatitis Internet hospital provides a direct channel to reach HBV patients. Expanding the platform's services and offerings, such as online consultations and prescription refills, can enhance customer engagement and drive sales. The online healthcare market in China is projected to reach $40 billion by 2027. Timeline: Expanding online services and increasing user engagement by 20% annually.
- Developing new prescription drugs: Biostar can invest in research and development to create new prescription drugs targeting unmet medical needs in China. The prescription drug market in China is projected to reach $300 billion by 2028. Timeline: Launching 1-2 new prescription drugs every 3 years.
- Strategic partnerships and acquisitions: Biostar can explore strategic partnerships or acquisitions to expand its product portfolio, market reach, and technological capabilities. The Chinese pharmaceutical market is consolidating, presenting opportunities for strategic alliances. Timeline: Pursuing 1-2 strategic partnerships or acquisitions over the next 5 years.
What Are BSPM's Competitive Advantages?
- Established distribution network in 28 provinces in China.
- Focus on traditional Chinese medicine.
- Key product targeting chronic hepatitis B, a significant health issue in China.
- Online platform providing direct access to HBV patients.
What Does BSPM Do?
Biostar Pharmaceuticals, Inc., established in 2007 and headquartered in Xianyang, China, is engaged in the development, manufacture, and marketing of pharmaceutical products. The company's portfolio includes both over-the-counter (OTC) and prescription medications, addressing a variety of diseases and conditions prevalent in the Chinese market. Its primary product is Xin Ao Xing Oleanolic Acid capsule, an OTC medicine indicated for chronic hepatitis B, a significant health concern in China. In addition to Xin Ao Xing, Biostar offers 12 other OTC products and 17 prescription-based pharmaceuticals, catering to a broad spectrum of healthcare needs. Biostar's OTC product line includes Ganwang compound paracetamol and amantadine hydrochloride capsule for cold and flu symptoms, Tianqi Dysmenorrhea capsule for menstrual pain, Deafness Tongqiao pills for ear-related issues, Wenweishu capsules for chronic gastritis, Zhitongtougu ointment for joint pain, and Chuzhang Zehaifu tablets for cataract. The company's prescription drugs cover areas such as cardiovascular health (Danshen granules and tablets), pediatric care (Taohuasan), and various other conditions including rhinitis, hyperthyroidism, and bacterial infections. Biostar also operates an online platform, the China Hepatitis Internet hospital, providing information and treatment options for HBV patients, as well as facilitating the purchase of HBV medicines. The company distributes its products through a network of distributors and sales personnel, reaching approximately 28 provinces across China.
What Products and Services Does BSPM Offer?
- Develops over-the-counter (OTC) pharmaceutical products.
- Manufactures prescription pharmaceutical products.
- Markets pharmaceutical products for various diseases and conditions.
- Offers Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B.
- Provides traditional Chinese medicines.
- Operates an online platform for HBV patients.
How Does BSPM Make Money?
- Develops and manufactures OTC and prescription pharmaceutical products.
- Sells products through distributors and a network of sales people in China.
- Operates an online platform (China Hepatitis Internet hospital) for HBV patients.
- Generates revenue from the sale of pharmaceutical products.
What Industry Does BSPM Operate In?
Biostar Pharmaceuticals operates within the Chinese pharmaceutical market, a large and rapidly growing sector driven by increasing healthcare expenditure and an aging population. The market is characterized by a mix of domestic and international players, with a growing demand for both OTC and prescription drugs. Biostar competes with other generic drug manufacturers, including BIOCQ, CLVR, CRFTF, CWWBF, and ELOX, as well as larger multinational pharmaceutical companies. The company's focus on traditional Chinese medicine and its established distribution network provide a competitive advantage in certain segments of the market.
Who Are BSPM's Key Customers?
- Patients in China seeking OTC medications for common ailments.
- Patients in China requiring prescription medications for various diseases.
- Hospitals and clinics in China that purchase pharmaceutical products.
- Distributors who sell Biostar's products to pharmacies and other retailers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 47 |
| 2026-08-26 | 47 |
| 2026-08-29 | 47 |
| 2026-09-01 | 47 |
| 2026-09-04 | 47 |
| 2026-09-07 | 47 |
| 2026-09-10 | 47 |
What changed?
The score has stayed at 47.
Over the same 18 days the stock moved +0.0%.
Company Profile
Biostar Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Xianyang, CN. The company is led by CEO Rong Hua Wang. BSPM has traded publicly since 2008.
Key Financial Metrics
Return on equity for Biostar Pharmaceuticals, Inc. stands at -14.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.4%, showing how much profit it generates from its asset base. A current ratio of 1.31 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Biostar Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.02 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
The most recent 11 insider filings for Biostar Pharmaceuticals, Inc. break down as 1 sales and 10 purchases. On net that is roughly 125K shares acquired (about $208K) — insiders putting money in tends to read as conviction.
BSPM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
Bear Case
- Negative profit margin.
- Limited financial resources.
- Dependence on a single key product (Xin Ao Xing).
- OTC listing indicates higher risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BSPM Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Dec 23, 2019
-
30 Biggest Movers From Yesterday
· Feb 8, 2018
-
18 Biggest Mid-Day Gainers For Tuesday
· Sep 20, 2016
BSPM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BSPM.
Price Targets
Wall Street price target analysis for BSPM.
BSPM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BSPM; grades run from A+ (80-100) to F (below 30).
Leadership: Ronghua Wang
CEO
Ronghua Wang serves as the CEO of Biostar Pharmaceuticals, Inc. He is responsible for managing the company's overall operations and strategic direction. His background includes experience in the pharmaceutical industry, with a focus on sales and marketing. He has been instrumental in expanding the company's distribution network and product portfolio. He oversees a workforce of approximately 200 employees.
Track Record: Under Ronghua Wang's leadership, Biostar Pharmaceuticals has focused on developing and marketing pharmaceutical products in China. Key milestones include the expansion of the company's OTC product line and the establishment of the China Hepatitis Internet hospital. However, the company's financial performance, as indicated by its negative profit margin, remains a challenge.
BSPM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biostar Pharmaceuticals may not meet the listing requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as exchange-listed companies. This can result in increased risks for investors due to the potential for less transparency and greater information asymmetry. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Determine the company's ownership structure and potential conflicts of interest.
- Check for any history of fraud or regulatory violations.
- Consult with a financial advisor before investing.
- Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
BSPM Healthcare Stock FAQ
Is BSPM a good stock?
Stock Expert AI does not rate BSPM buy, sell or hold. Biostar Pharmaceuticals, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about BSPM stock?
(BSPM). Given its OTC listing and negative profit margin, investors should conduct thorough due diligence and carefully assess the risks associated with investing in this company.
What are the main risks for BSPM?
The main risks for Biostar Pharmaceuticals, Inc. include its negative profit margin, limited financial resources, and dependence on a single key product.
What are the key factors to evaluate for BSPM?
Evaluate BSPM on fundamentals, analyst consensus, and risk factors. Offers both OTC and prescription drugs, diversifying its revenue streams. Not financial advice.
How frequently does BSPM data refresh on this page?
BSPM's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BSPM's recent stock price performance?
Biostar Pharmaceuticals, Inc. (BSPM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established distribution network in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BSPM overvalued or undervalued right now?
Biostar Pharmaceuticals, Inc. (BSPM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BSPM?
Yes, most major brokerages offer fractional shares of Biostar Pharmaceuticals, Inc. (BSPM) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC stocks carry higher risks than exchange-listed stocks.